Crinetics Pharmaceuticals

$15.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-0.62%) As of 5:24 PM UTC today

Why Robinhood?

You can buy or sell CRNX and other stocks, options, and ETFs commission-free!

About CRNX

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA. The listed name for CRNX is Crinetics Pharmaceuticals, Inc. Common Stock.

CEO
Scott R. Struthers
Employees
68
Headquarters
San Diego, California
Founded
2008
Market Cap
509.36M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
115.68K
High Today
$15.98
Low Today
$15.12
Open Price
$15.66
Volume
38.81K
52 Week High
$23.70
52 Week Low
$10.63

CRNX Earnings

-$0.71
-$0.47
-$0.24
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 9, Pre-Market

You May Also Like

AZPN
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure